RT
Rondo Therapeutics at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
Rondo Therapeutics takes part in 4 sessions at Antibody Engineering 2026 in San Diego. Its program centers on T cell engagers and on antibodies that bind more than two targets. Its research pairs one engager that switches T cells on with another that gives them a second, boosting signal, to treat ovarian cancer.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
RT Rondo Therapeutics Hayward, CA | |
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors. | Chair Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Chair Tue Dec 15 2:25pm–2:30pm Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Chair Wed Dec 16 8:10am–8:15am |
Find decision makers at Rondo Therapeutics
Tell us what you sell and we’ll find the people at Rondo Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction